OpCo · Form 13F-HR
Operating company 13F-HR
Form 13F-HR investment books of operating companies and corporate parents (corporate treasury, insurance float, holding-company equity books). Separate from featured managers — Newest 13Fs. For issuer 8-K / 10-Q / 10-K, use Company filings.
OpCo 13F-HR·pharma
3 shown
companies
3
today
0
7d
3
14d
3
tracked
~26
updates
newest filed first · top holdings · open company or book
| company | period | type | top holds | aum | # | links |
|---|---|---|---|---|---|---|
| 7 Aug yesterday 1 | ||||||
| Merck & Co. pharma | 2026 Q2 | 13F-HR | $526M | 13 | profile activity | |
| 6 Aug 2d ago 1 | ||||||
| Johnson & Johnson pharma | 2026 Q2 | 13F-HR | — | $799M | 15 | profile activity |
| 3 Aug 5d ago 1 | ||||||
| Gilead Sciences pharma | 2026 Q2 | 13F-HR | $1.6B | 5 | profile activity | |
Latest book per operating company we track. QoQ narrative (soft language) → OpCo 13F-HR changes. Amendment trails for featured managers stay on Newest 13Fs. Berkshire, Markel, and dual-identity names stay on featured managers. Values as filed. Not investment advice.